StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a report issued on Thursday. The brokerage issued a sell rating on the stock.
Oragenics Stock Up 1.9 %
OGEN opened at $1.07 on Thursday. The firm has a fifty day moving average price of $1.48. Oragenics has a fifty-two week low of $1.00 and a fifty-two week high of $7.74. The stock has a market capitalization of $4.79 million, a PE ratio of -0.12 and a beta of 0.40.
Oragenics (NYSE:OGEN – Get Free Report) last announced its quarterly earnings results on Friday, March 29th. The company reported ($5.48) earnings per share for the quarter.
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
See Also
- Five stocks we like better than Oragenics
- Short Selling: How to Short a Stock
- MarketBeat Week in Review – 4/29 – 5/3
- What Are Dividends? Buy the Best Dividend Stocks
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Using the MarketBeat Stock Split Calculator
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
